BEIJING: Intense Chinese demand for initial public offerings on the country’s new stock board is sending valuations for new listings sky-high.
A biotech firm priced its shares at about 468 times reported earnings, according to a Shanghai exchange filing. That’s almost triple the most expensive of last week’s inaugural batch of debuts.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
